- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of methocarbamol.
Adjunct for acute musculo-skeletal disorders with painful muscle spasm
The recommended dose is 1500mg three to four times daily.
In severe cases up to 1500mg five times daily may be taken.
750mg four times a day (half the maximum adult dose) or less may produce a therapeutic response.
Patients with Hepatic Impairment
The elimination half-life of methocarbamol may be prolonged in patients with chronic hepatic disease. Consider increasing the dose interval.
Children under 18 years
Precautions and Warnings
Glucose-galactose malabsorption syndrome
Advise patient drowsiness may affect ability to drive or operate machinery
Some formulations contain lactose
Some products may contain soya or soya derivative
May affect results of some laboratory tests
Reduce dose in elderly
Take with sufficient water.
Pregnancy and Lactation
Use methocarbamol with caution during pregnancy.
The manufacturer does not recommend using methocarbamol during pregnancy unless the potential benefits outweigh the possible hazards. At the time of writing there is limited published information regarding the use of methocarbamol during pregnancy. Although potential risks are unknown, there have been rare reports of foetal and congenital abnormalities following exposure to methocarbamol.
Use methocarbamol with caution during breastfeeding.
The manufacturer advises caution if methocarbamol is used when breastfeeding. Animal data reports levels of methocarbamol in the breast milk, however presence in human breast milk and its effects on exposed infants are unknown.
Effects on Laboratory Tests
Methocarbamol may cause colour interference in certain screening tests for 5-hydroxyindolacetic acid (5-HIAA) using nitrosoaphthol reagent and in screening tests for urinary vanillymandelic acid (VMA) using the Gitlow method.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: August 2021
Summary of Product Characteristics: Methocarbamol 1500mg film-coated tablets. Neuraxpharm UK Limited. Revised March 2021.
Summary of Product Characteristics: Robaxin-750. Almirall Limited. Revised July 2017.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.